BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:VX-407 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of VX-407\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07868926-10842@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:VX-407: Phase 1 readout est. (NCT07868926)
DESCRIPTION:VX-407\, phase 1\, Autosomal Dominant Polycystic Kidney Disease
 .\nStudy: Absorption\, Distribution\, Metabolism\, and Excretion of 14C-VX
 -407 After a Single Oral Dose\nEstimated primary completion: 15 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/vx-407#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07868926
URL:https://assetmemo.bio/drug/vx-407#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07792408-10842@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20270311
DTEND;VALUE=DATE:20270312
SUMMARY:VX-407: Phase 1 readout est. (NCT07792408)
DESCRIPTION:VX-407\, phase 1\, Autosomal Dominant Polycystic Kidney Disease
 .\nStudy: Effects of VX-407 on the Pharmacokinetics of Combined Oral Contr
 aceptives\nEstimated primary completion: 11 March 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/vx-407#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07792408
URL:https://assetmemo.bio/drug/vx-407#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07161037-10842@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:VX-407: Phase 2 readout est. (NCT07161037)
DESCRIPTION:VX-407\, phase 2\, Autosomal Dominant Polycystic Kidney Disease
 .\nStudy: Phase 2a Study of VX-407 in Participants With ADPKD Who Have a S
 ubset of PKD1 Gene Variants (AGLOW)\nEstimated primary completion: 22 July
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/vx-407#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07161037
URL:https://assetmemo.bio/drug/vx-407#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
